VRTX
Vertex Pharmaceuticals Incorporated
NASDAQ · Healthcare · Biotechnology · US
$546.12
−2.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.6B | 12.1B | 11.0B | 9.9B | 8.9B |
| Cost of Revenue | 1.8B | 1.8B | 1.5B | 1.3B | 1.1B |
| Gross Profit | 10.9B | 10.3B | 9.5B | 8.6B | 7.9B |
| Operating Expenses | |||||
| R&D Expense | 4.0B | 3.8B | 3.6B | 3.2B | 2.7B |
| SG&A Expense | 2.0B | 1.8B | 1.5B | 1.1B | 944.7M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 20.6M | — | 4.6B | 475.5M | (57.5M) |
| Total Operating Expenses | 6.0B | 5.5B | 9.7B | 4.8B | 3.5B |
| Cost and Expenses | 7.8B | 7.3B | 11.3B | 6.0B | 4.6B |
| Operating Income (EBIT) | 4.9B | 4.8B | (232.9M) | 3.8B | 4.3B |
| Non-Operating | |||||
| Interest Income | 483.0M | 490.9M | 598.1M | 614.7M | 144.6M |
| Interest Expense | 6.6M | 13.3M | 30.6M | 44.1M | 54.8M |
| Net Interest Income | 476.4M | 477.6M | 567.5M | 570.6M | 89.8M |
| Other Non-Op Income/Expense | 402.9M | (117.5M) | 481.4M | 547.8M | (75.0M) |
| Non-Operating Income (excl Interest) | (409.5M) | 104.2M | (512.0M) | (591.9M) | 20.2M |
| EBT (Pre-Tax Income) | 5.3B | 4.6B | 248.5M | 4.4B | 4.2B |
| Income Tax Expense | 869.3M | 690.0M | 784.1M | 760.2M | 910.4M |
| Bottom Line | |||||
| Net Income | 4.4B | 4.0B | (535.6M) | 3.6B | 3.3B |
| Earnings from Cont. Ops | 4.4B | 4.0B | (535.6M) | 3.6B | 3.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.4B | 4.0B | (535.6M) | 3.6B | 3.3B |
| Per Share | |||||
| Basic EPS | $17.32 | $15.46 | ($2.08) | $14.05 | $12.97 |
| Diluted EPS | $17.18 | $15.32 | ($2.08) | $13.89 | $12.82 |
| Revenue Per Share | $49.72 | $47.22 | $42.80 | $38.30 | $34.87 |
| Shares | |||||
| Basic Shares Outstanding | 253.9M | 255.7M | 257.5M | 257.7M | 256.1M |
| Diluted Shares Outstanding | 255.7M | 258.0M | 257.9M | 260.5M | 259.1M |
| Profitability Metrics | |||||
| EBITDA | 5.4B | 4.9B | 486.3M | 4.6B | 4.4B |
| D&A | 163.0M | 207.2M | 205.8M | 181.3M | 148.3M |
| EBIT | 5.3B | 4.7B | 279.1M | 4.4B | 4.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026